Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
4
SER Quote, Financials, Valuation and Earnings
Last price:
$2.63
Seasonality move
:
-2.18%
Day range:
$2.59 - $2.89
52-week range:
$2.66 - $7.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
188.43x
P/B ratio:
--
Volume:
14.2K
Avg. volume:
15.4K
1-year change:
-56.66%
Market cap:
$28.3M
Revenue:
$56K
EPS (TTM):
-$1.45
Analysts' Opinion
-
Consensus RatingSerina Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.00, Serina Therapeutics, Inc. has an estimated upside of 389.27% from its current price of $2.66.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $11.00 representing 100% downside risk from its current price of $2.66.
Fair Value
-
According to the consensus of 1 analyst, Serina Therapeutics, Inc. has 389.27% upside to fair value with a price target of $13.00 per share.
SER vs. S&P 500
-
Over the past 5 trading days, Serina Therapeutics, Inc. has underperformed the S&P 500 by -14.73% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Serina Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Serina Therapeutics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Serina Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Serina Therapeutics, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Serina Therapeutics, Inc. reported earnings per share of -$0.44.
Enterprise value:
27.7M
EV / Invested capital:
5.78x
Price / LTM sales:
188.43x
EV / EBIT:
--
EV / Revenue:
192.27x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.85x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$32K
Return On Assets:
-156.79%
Net Income Margin (TTM):
-10066.67%
Return On Equity:
--
Return On Invested Capital:
-4192.02%
Operating Margin:
-4280.77%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $74K | $3.2M | $144K | $14K | -- | |
| Gross Profit | -$44K | $3M | $32K | -$42K | -$17K | |
| Operating Income | -$5.2M | -$11.3M | -$23.1M | -$5.3M | -$6.4M | |
| EBITDA | -$5M | -$11.1M | -$23M | -$5.3M | -$6.4M | |
| Diluted EPS | -$1.96 | -$4.30 | -$1.45 | $0.13 | -$0.44 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.5M | $1.2M | $1.1M | $5.4M | $11.5M | |
| Total Assets | $2.4M | $2M | $12.2M | $7.4M | $12.4M | |
| Current Liabilities | $6.6M | $8.8M | $3.2M | $13.5M | $8.8M | |
| Total Liabilities | $12.4M | $17.2M | $3.9M | $21.3M | $10.8M | |
| Total Equity | -$10M | -$15.1M | $8.3M | -$13.8M | $1.6M | |
| Total Debt | $11.4M | $15.6M | $693K | $11.3M | $3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$3.9M | -$12.4M | -$14.9M | -$3M | -$3.9M | |
| Cash From Investing | -$434K | -$87K | -$62K | -$3K | -$13K | |
| Cash From Financing | $11.6M | $8.2M | $17M | $86K | $6.4M | |
| Free Cash Flow | -$4.4M | -$12.5M | -$14.9M | -$3M | -$3.9M | |
SER
Sector
Market Cap
$28.3M
$28.3M
Price % of 52-Week High
33.55%
51.3%
Dividend Yield
0%
0%
Shareholder Yield
-18.63%
-1.42%
1-Year Price Total Return
-56.66%
-17.78%
Beta (5-Year)
1.061
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.04
200-day SMA
Sell
Level
$5.08
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$3.45
Relative Strength Index (RSI14)
Sell
Level
28.21
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$4.16
MACD (12, 26)
Buy
Level
0.39
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-12.4388)
Sell
CA Score
(Annual)
Level (-11.1638)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (10.4471)
Sell
Piotroski F Score
(Annual)
Level (1)
Sell
Quality Ratio Score
Level (3)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Serina Therapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the research and development of polymer technology. Its POZ technology is designed to optimize drug delivery to maximize compliance, therapeutic outcomes, safety, and quality of life for patients. It also offers drugs to treat neurological diseases, cancer, and pain. The company was founded by J. Milton Harris and Michael D. Bentley on March 26, 2024 and is headquartered in Huntsville, AL.
Stock Forecast FAQ
In the current month, SER has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The SER average analyst price target in the past 3 months is $13.00.
-
Where Will Serina Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Serina Therapeutics, Inc. share price will rise to $13.00 per share over the next 12 months.
-
What Do Analysts Say About Serina Therapeutics, Inc.?
Analysts are divided on their view about Serina Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Serina Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $11.00.
-
What Is Serina Therapeutics, Inc.'s Price Target?
The price target for Serina Therapeutics, Inc. over the next 1-year time period is forecast to be $13.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is SER A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Serina Therapeutics, Inc. is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of SER?
You can purchase shares of Serina Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Serina Therapeutics, Inc. shares.
-
What Is The Serina Therapeutics, Inc. Share Price Today?
Serina Therapeutics, Inc. was last trading at $2.63 per share. This represents the most recent stock quote for Serina Therapeutics, Inc.. Yesterday, Serina Therapeutics, Inc. closed at $2.66 per share.
-
How To Buy Serina Therapeutics, Inc. Stock Online?
In order to purchase Serina Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get SER Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
SER
Sector
P/E ratio
--
23.99x
PEG ratio
--
-0.01x
P/B ratio
--
1.80x
Price / LTM sales
188.43x
1.59x
Growth Metrics
SER
Sector
Revenue growth
-100%
4.62%
Earnings growth
-186.55%
10.71%
Revenue (5-year growth)
-49.64%
6.5%
Earnings forecast
-$0.53
-$0.20
Profitability
SER
Sector
Profitability FY 2024
-$138K
$3.6M
Return on invested capital
-4192.02%
-31.84%
Return on assets
-156.79%
-27.96%
Return on equity
--
-37.47%
Earnings Date
Last Earnings Date
Dec
20
Next Earnings Date
Dec
20
Estimated Next Earnings Date
Mar
21
Balance Sheet
SER
Sector
Total cash
$8.6M
$26.4M
Short term investments
--
$25.7M
Total assets
$6.7M
$78M
Long term debt
$3M
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 11.91% over the past day.
Sell
36
INSP alert for Dec 20
Inspire Medical Systems, Inc. [INSP] is up 1.39% over the past day.
Sell
40
INSM alert for Dec 20
Insmed, Inc. [INSM] is up 4.79% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
